Higher vitamin D levels at the start of treatment are associated with longer survival without cancer progression in men with advanced prostate cancer receiving hormone-blocking therapy, according to a 2026 study of 273 patients. For every 10-unit increase in vitamin D, cancer progression risk dropped 36 percent. However, this research does not prove vitamin D supplements treat cancer, and doctors should not yet use this finding to guide treatment decisions without further prospective validation.
Researchers studied whether vitamin D levels could help doctors predict how well prostate cancer patients would respond to treatment. They looked at 273 men with advanced prostate cancer who were taking hormone-blocking medications. According to Gram Research analysis, men with higher vitamin D levels at the start of treatment tended to live longer without their cancer getting worse. The study created a prediction tool that included vitamin D along with other health factors, and this tool performed better than models without vitamin D. However, the researchers emphasize this doesn’t mean vitamin D supplements will help treat cancer, and more research is needed before doctors use this in practice.
Key Statistics
A 2026 study of 273 men with advanced prostate cancer found that higher baseline vitamin D levels were associated with 36 percent lower risk of cancer progression for every 10-unit increase in vitamin D (p<0.001).
Adding vitamin D measurement to a prostate cancer prediction model improved accuracy from 71.2 percent to 74 percent in the training cohort and achieved 76 percent accuracy in external validation across 81 additional patients.
In a multicenter analysis of 273 prostate cancer patients, vitamin D provided modest but statistically significant prognostic information beyond standard clinical factors like age, cancer grade, and PSA level.
The Quick Take
- What they studied: Whether vitamin D levels in the blood could predict how long men with advanced prostate cancer would survive without their disease getting worse while on standard cancer treatment.
- Who participated: 273 men with newly diagnosed advanced prostate cancer that had spread to other parts of the body. They were treated at hospitals in Turkey between 2021 and 2026. Most were receiving hormone-blocking medications as their main treatment.
- Key finding: Men with higher baseline vitamin D levels had significantly better outcomes. For every 10-unit increase in vitamin D, the risk of cancer progression dropped by 36 percent. Adding vitamin D information to a prediction model improved its accuracy from 71.2 percent to 74 percent.
- What it means for you: If you have prostate cancer, your vitamin D level might provide additional information about your prognosis alongside other clinical factors. However, this research does not prove that taking vitamin D supplements will improve your cancer outcomes. Talk with your oncologist about what your vitamin D level means for your specific situation.
The Research Details
This was a retrospective study, meaning researchers looked back at medical records of patients who had already received treatment. They included 273 men with advanced prostate cancer who started hormone-blocking therapy between 2021 and 2026. The researchers divided the patients into two groups: a training group of 192 men from one hospital and a validation group of 81 men from two other hospitals. The validation group helped confirm whether the findings from the first group would hold true in different patient populations.
The researchers measured vitamin D levels in blood samples taken before treatment started. They then tracked how long it took for each patient’s cancer to progress or worsen. They also recorded other important health information like age, cancer grade, how much cancer was present, PSA levels (a cancer marker), and hemoglobin (a blood protein). Using statistical methods, they built a prediction model that combined all these factors to estimate each patient’s risk of cancer progression.
The study used a technique called LASSO regression to identify which factors were most important for prediction. They tested their model’s accuracy using a method called bootstrap validation, which involves repeatedly testing the model on different samples of the data. This approach helps ensure the results are reliable and not just due to chance.
This research approach matters because doctors need better tools to predict which prostate cancer patients will do well and which ones might need more aggressive treatment. Current prediction models rely on clinical factors like cancer stage and PSA levels, but they’re not perfect. By identifying that vitamin D adds useful information, researchers can build more accurate prediction tools. The external validation step is particularly important because it proves the findings work in different patient populations and hospitals, not just the original group studied.
This study has several strengths: it included patients from multiple hospitals, used external validation to confirm results, and measured vitamin D objectively from blood samples. However, there are important limitations. The study was retrospective, meaning it relied on existing medical records rather than prospectively following patients forward in time. The researchers did not randomly assign patients to different vitamin D levels, so they cannot prove vitamin D causes better outcomes. The sample size, while reasonable, was relatively modest. The study was conducted in Turkey, so results may not apply equally to all populations. Most importantly, the researchers found only a modest improvement in prediction accuracy, and they explicitly state this does not prove that vitamin D supplements would help treat cancer.
What the Results Show
The main finding was that higher baseline vitamin D levels were strongly associated with longer progression-free survival, meaning the time before cancer got worse. For every 10-unit increase in vitamin D (measured in ng/mL), the risk of cancer progression decreased by 36 percent. This relationship was statistically significant, with a p-value less than 0.001, meaning there’s less than a 0.1 percent chance this finding occurred by random chance.
When the researchers added vitamin D to their prediction model alongside age, cancer grade, disease volume, PSA level, and hemoglobin, the model’s performance improved. The model’s accuracy increased from 71.2 percent to 74 percent, a modest but meaningful improvement. The improvement was confirmed in the external validation group, where the model achieved 76 percent accuracy. This consistency across different patient groups strengthens confidence in the findings.
The researchers also performed exploratory analyses on overall survival (how long patients lived overall), though this was not the main focus of the study. The patterns were similar to what they found for progression-free survival, suggesting vitamin D’s association with outcomes may extend beyond just cancer progression.
Interestingly, the improvement in prediction accuracy was consistent across different time points. The model performed well at predicting outcomes at both 1 year and 2 years after treatment started, suggesting vitamin D’s prognostic value is stable over time.
The study examined how well the prediction model worked at different time points and found consistent performance. The model maintained good accuracy at both 1-year and 2-year follow-up periods. The researchers also looked at calibration, which means checking whether the model’s predictions matched what actually happened. The model was well-calibrated, meaning when it predicted a 50 percent chance of progression, about 50 percent of patients actually progressed. This suggests the model provides reliable risk estimates that doctors could use in clinical conversations with patients.
This research adds to growing evidence that vitamin D may play a role in cancer outcomes. Previous studies have suggested vitamin D deficiency is associated with worse outcomes in various cancers, but research specifically in advanced prostate cancer treated with modern hormone-blocking drugs is limited. This study is among the first to systematically evaluate vitamin D’s prognostic value in this specific patient population and to validate findings in an external cohort. The modest improvement in prediction accuracy aligns with other research showing that single biomarkers typically add incremental rather than dramatic improvements to existing prediction models.
The researchers clearly acknowledged several important limitations. First, this was a retrospective study using existing medical records, which cannot prove that vitamin D causes better outcomes, only that it’s associated with them. Second, vitamin D levels were measured only once at baseline, so the study doesn’t know whether vitamin D levels changed during treatment or whether that would matter. Third, the study was conducted in Turkey and may not apply equally to other populations with different genetics, sun exposure, and dietary patterns. Fourth, the improvement in prediction accuracy, while statistically significant, was modest (about 3 percentage points), raising questions about practical clinical value. Fifth, the study was not prospectively registered, meaning the researchers didn’t pre-specify their analysis plan before looking at the data. Finally, and most importantly, the study does not prove that vitamin D supplementation would help treat cancer, and the researchers explicitly warn against drawing that conclusion.
The Bottom Line
Based on this research, vitamin D level appears to provide modest additional prognostic information for men with advanced prostate cancer on hormone-blocking therapy. However, the evidence is not yet strong enough to recommend routine vitamin D supplementation specifically for cancer treatment. If you have prostate cancer, ask your doctor to check your vitamin D level as part of comprehensive health assessment, but don’t assume supplements will improve your cancer outcomes. Maintain adequate vitamin D through sun exposure and diet as part of general health maintenance. Prospective studies are needed before this prediction model should be used in routine clinical practice.
This research is most relevant to men with newly diagnosed advanced prostate cancer that has spread to other parts of the body and who are starting hormone-blocking therapy. It may also interest oncologists and urologists who treat prostate cancer. Men with early-stage prostate cancer or those not receiving hormone-blocking therapy should not assume these findings apply to them. The general public should not interpret this as evidence that vitamin D supplements prevent or treat cancer.
If vitamin D were to influence cancer outcomes, the effects would likely develop over months rather than weeks. In this study, researchers tracked patients for extended periods and found vitamin D’s association with progression-free survival was apparent over 1 to 2 years of follow-up. However, remember that this study shows association, not causation, so even if you optimize your vitamin D level, you shouldn’t expect immediate changes in your cancer status.
Frequently Asked Questions
Does vitamin D supplementation help treat prostate cancer?
This study does not prove vitamin D supplements treat cancer. It only shows that men with naturally higher vitamin D levels had better outcomes. The researchers explicitly state their findings do not establish treatment benefit from supplementation. Prospective studies are needed to test whether supplements actually help.
What vitamin D level should prostate cancer patients aim for?
This study doesn’t specify a target vitamin D level for cancer patients. It found that higher levels were associated with better outcomes, but the relationship was continuous rather than having a specific cutoff. Discuss your individual vitamin D target with your oncologist based on your health status and local guidelines.
Can vitamin D predict how my prostate cancer will progress?
Vitamin D provides modest additional information for predicting progression risk when combined with other clinical factors like cancer stage and PSA level. However, it’s not a strong predictor on its own. Your doctor should consider multiple factors together, not vitamin D alone, when discussing your prognosis.
Should I get my vitamin D level tested if I have prostate cancer?
Checking vitamin D as part of comprehensive health assessment is reasonable, especially since vitamin D deficiency is common and affects overall health. However, don’t expect vitamin D testing alone to change your cancer treatment plan. Discuss with your oncologist whether testing fits your individual care.
How reliable is this vitamin D prediction model for prostate cancer?
The model showed 71 to 76 percent accuracy in predicting 1 to 2-year outcomes, which is modest improvement over existing models. The external validation in a different patient group strengthens confidence. However, the researchers emphasize prospective validation is needed before using this model in routine clinical practice.
Want to Apply This Research?
- Track your vitamin D level every 3 to 6 months if you have prostate cancer. Record the specific ng/mL value, the date tested, and any changes in your cancer markers or treatment. This allows you to see patterns over time and discuss trends with your oncologist.
- Work with your doctor to maintain optimal vitamin D levels through a combination of safe sun exposure (10 to 30 minutes several times per week), vitamin D-rich foods like fatty fish and fortified dairy, and supplementation if recommended. Log these activities in your health app to build consistency.
- Create a quarterly health review where you compare your vitamin D levels, PSA values, and cancer progression status. Share this data with your oncology team to see whether vitamin D trends correlate with your individual outcomes. This personalized tracking helps you and your doctor make informed decisions about your care.
This research describes an association between vitamin D levels and prostate cancer outcomes but does not prove that vitamin D supplements treat or prevent cancer. These findings are from a retrospective study and have not yet been validated in prospective clinical trials. Do not start, stop, or change vitamin D supplementation based on this research without consulting your oncologist. This information is for educational purposes and should not replace professional medical advice. If you have prostate cancer or are at risk for prostate cancer, work with your healthcare team to develop an individualized treatment and monitoring plan.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.